94 related articles for article (PubMed ID: 28104440)
1. Twin-screw extruded lipid implants containing TRP2 peptide for tumour therapy.
Even MP; Bobbala S; Gibson B; Hook S; Winter G; Engert J
Eur J Pharm Biopharm; 2017 May; 114():79-87. PubMed ID: 28104440
[TBL] [Abstract][Full Text] [Related]
2. In vivo investigation of twin-screw extruded lipid implants for vaccine delivery.
Even MP; Young K; Winter G; Hook S; Engert J
Eur J Pharm Biopharm; 2014 Jul; 87(2):338-46. PubMed ID: 24607791
[TBL] [Abstract][Full Text] [Related]
3. Impact of implant composition of twin-screw extruded lipid implants on the release behavior.
Even MP; Bobbala S; Kooi KL; Hook S; Winter G; Engert J
Int J Pharm; 2015 Sep; 493(1-2):102-10. PubMed ID: 26188320
[TBL] [Abstract][Full Text] [Related]
4. Immunostimulatory lipid implants containing Quil-A and DC-cholesterol.
Myschik J; McBurney WT; Rades T; Hook S
Int J Pharm; 2008 Nov; 363(1-2):91-8. PubMed ID: 18692555
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis.
Xu Z; Ramishetti S; Tseng YC; Guo S; Wang Y; Huang L
J Control Release; 2013 Nov; 172(1):259-265. PubMed ID: 24004885
[TBL] [Abstract][Full Text] [Related]
6. Multi-functional nanocomplex codelivery of Trp2 and R837 to activate melanoma-specific immunity.
Ji Z; Tan Z; Li M; Tao J; Guan E; Du J; Hu Y
Int J Pharm; 2020 May; 582():119310. PubMed ID: 32276088
[TBL] [Abstract][Full Text] [Related]
7. Cationic micelle delivery of Trp2 peptide for efficient lymphatic draining and enhanced cytotoxic T-lymphocyte responses.
Zeng Q; Jiang H; Wang T; Zhang Z; Gong T; Sun X
J Control Release; 2015 Feb; 200():1-12. PubMed ID: 25540903
[TBL] [Abstract][Full Text] [Related]
8. New insights into process understanding of solid lipid extrusion (SLE) of extruded lipid implants for sustained protein delivery.
Vollrath M; Engert J; Winter G
Eur J Pharm Biopharm; 2018 Sep; 130():11-21. PubMed ID: 29913270
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of lipid sustained release implants containing imiquimod, alpha-galactosylceramide, or Quil-A.
Myschik J; McBurney WT; Hennessy T; Rades T; Hook S
Pharmazie; 2008 Sep; 63(9):686-92. PubMed ID: 18819523
[TBL] [Abstract][Full Text] [Related]
10. Immunostimulatory biodegradable implants containing the adjuvant Quil-A--Part II: In vivo evaluation.
Myschik J; McBurney WT; Hennessy T; Phipps-Green A; Rades T; Hook S
J Drug Target; 2008 Apr; 16(3):224-32. PubMed ID: 18365884
[TBL] [Abstract][Full Text] [Related]
11. Immunostimulatory biodegradable implants containing the adjuvant Quil-A--Part I: Physicochemical characterisation.
Myschik J; Eberhardt F; Rades T; Hook S
J Drug Target; 2008 Apr; 16(3):213-23. PubMed ID: 18365883
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant.
Jérôme V; Graser A; Müller R; Kontermann RE; Konur A
J Immunother; 2006; 29(3):294-305. PubMed ID: 16699372
[TBL] [Abstract][Full Text] [Related]
13. Trp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model.
Vasievich EA; Ramishetti S; Zhang Y; Huang L
Mol Pharm; 2012 Feb; 9(2):261-8. PubMed ID: 22142394
[TBL] [Abstract][Full Text] [Related]
14. Upscaling and in-line process monitoring via spectroscopic techniques of ethylene vinyl acetate hot-melt extruded formulations.
Almeida A; Saerens L; De Beer T; Remon JP; Vervaet C
Int J Pharm; 2012 Dec; 439(1-2):223-9. PubMed ID: 23018111
[TBL] [Abstract][Full Text] [Related]
15. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
[TBL] [Abstract][Full Text] [Related]
16. Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity.
Kojima N; Biao L; Nakayama T; Ishii M; Ikehara Y; Tsujimura K
J Control Release; 2008 Jul; 129(1):26-32. PubMed ID: 18485512
[TBL] [Abstract][Full Text] [Related]
17. Biodegradable implants for the delivery of veterinary vaccines: design, manufacture and antibody responses in sheep.
Walduck AK; Opdebeeck JP; Benson HE; Prankerd R
J Control Release; 1998 Feb; 51(2-3):269-80. PubMed ID: 9685925
[TBL] [Abstract][Full Text] [Related]
18. Chitosan hydrogels containing liposomes and cubosomes as particulate sustained release vaccine delivery systems.
Gordon S; Young K; Wilson R; Rizwan S; Kemp R; Rades T; Hook S
J Liposome Res; 2012 Sep; 22(3):193-204. PubMed ID: 22188610
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic studies on the release of lysozyme from twin-screw extruded lipid implants.
Sax G; Winter G
J Control Release; 2012 Oct; 163(2):187-94. PubMed ID: 22964391
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant.
Yamano T; Kaneda Y; Huang S; Hiramatsu SH; Hoon DS
Mol Ther; 2006 Jan; 13(1):194-202. PubMed ID: 16112911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
